{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:22:56Z","timestamp":1794306176602,"version":"4.9.0"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ajo.2026.07.063","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T15:11:12Z","timestamp":1787411472000},"page":"813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comment on: \u201cGlucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy\u201d"],"prefix":"10.1016","volume":"292","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9458-5665","authenticated-orcid":false,"given":"Joshua","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2026.07.063_bib0001","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ajo.2026.04.021","article-title":"Glucagon-like peptide-1 receptor agonists and risk of systemic and ocular vascular complications in patients with type 2 diabetes and diabetic retinopathy","volume":"288","author":"Shah","year":"2026","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.07.063_bib0002","article-title":"Comparative dementia and Parkinson\u2019s disease risk associated with melatonin, benzodiazepine, or zolpidem use in patients with sleep disorders: a retrospective cohort study","author":"Chang","year":"2026","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajo.2026.07.063_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2026.109421","article-title":"Association of cannabis use and lung cancer: a retrospective cohort study","volume":"216","author":"Gallagher","year":"2026","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.ajo.2026.07.063_bib0004","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ophtha.2026.02.018","article-title":"Uses and abuses of big data in ophthalmology research","volume":"133","author":"Lee","year":"2026","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2026.07.063_bib0005","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.annonc.2026.04.013","article-title":"GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults","volume":"37","author":"Hsu","year":"2026","journal-title":"Ann Oncol"},{"issue":"28","key":"10.1016\/j.ajo.2026.07.063_bib0006","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:32:25Z","timestamp":1794303145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426004782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":6,"alternative-id":["S0002939426004782"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.07.063","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comment on: \u201cGlucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy\u201d","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.07.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.04.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}